Kieran G Foley1, Adam Christian2, James Peaker2, Christopher Marshall3, Emiliano Spezi4, Howard Kynaston1, Ashley Roberts5. 1. 1 Division of Cancer & Genetics, School of Medicine, Cardiff University , Cardiff , UK. 2. 2 Department of Pathology, University Hospital of Wales , Cardiff , UK. 3. 3 Wales Research and Diagnostic Positron Emission Tomography Imaging Centre (PETIC), Cardiff University , Cardiff , UK. 4. 4 School of Engineering, Cardiff University , Cardiff , UK. 5. 5 Department of Radiology, University Hospital of Wales , Cardiff , UK.
Abstract
OBJECTIVES: This pilot study investigated the association of four PET image features and cyclo-oxygenase-2 (COX-2) expression in patients with oesophageal adenocarcinoma. The prognostic significance of these biomarkers was also assessed. METHODS: 50 consecutive patients [median age = 68 (range 47 - 84), males = 45) with oesophageal adenocarcinoma had PET/CT staging between January 2011 and July 2015. The maximum and mean standardised uptake values (SUVmax and SUVmean), metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG) were calculated from the primary tumour. Their association with COX-2 status was assessed using Mann-Whitney U tests. Kaplan-Meier and Cox regression analysis tested their prognostic significance. A p-value < 0.05 was considered statistically significant. RESULTS: 32 tumours (64.0%) were COX-2 positive. There was a significant association between SUVmean and COX-2 status (p = 0.019). TLG (hazard ratio (HR) 1.001, 95 % confidence intervals (CI) 1.000 - 1.002, p = 0.018) was significantly associated with overall survival on multivariable analysis. CONCLUSIONS: This study investigated the association between PET image features and COX-2 expression in oesophageal adenocarcinoma. The preliminary results signal that a combination of TLG (calculated as product of MTV and SUVmean) and COX-2 status may be a strong and clinically important prognostic biomarker. Our research group are planning a prospective, multi-centre study to validate these findings. ADVANCES IN KNOWLEDGE: Mean standardised uptake value (SUVmean) on PET imaging is associated with COX-2 expression in oesophageal adenocarcinoma.
OBJECTIVES: This pilot study investigated the association of four PET image features and cyclo-oxygenase-2 (COX-2) expression in patients with oesophageal adenocarcinoma. The prognostic significance of these biomarkers was also assessed. METHODS: 50 consecutive patients [median age = 68 (range 47 - 84), males = 45) with oesophageal adenocarcinoma had PET/CT staging between January 2011 and July 2015. The maximum and mean standardised uptake values (SUVmax and SUVmean), metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG) were calculated from the primary tumour. Their association with COX-2 status was assessed using Mann-Whitney U tests. Kaplan-Meier and Cox regression analysis tested their prognostic significance. A p-value < 0.05 was considered statistically significant. RESULTS: 32 tumours (64.0%) were COX-2 positive. There was a significant association between SUVmean and COX-2 status (p = 0.019). TLG (hazard ratio (HR) 1.001, 95 % confidence intervals (CI) 1.000 - 1.002, p = 0.018) was significantly associated with overall survival on multivariable analysis. CONCLUSIONS: This study investigated the association between PET image features and COX-2 expression in oesophageal adenocarcinoma. The preliminary results signal that a combination of TLG (calculated as product of MTV and SUVmean) and COX-2 status may be a strong and clinically important prognostic biomarker. Our research group are planning a prospective, multi-centre study to validate these findings. ADVANCES IN KNOWLEDGE: Mean standardised uptake value (SUVmean) on PET imaging is associated with COX-2 expression in oesophageal adenocarcinoma.
Authors: Kieran G Foley; Patrick Fielding; Wyn G Lewis; Alex Karran; David Chan; Paul Blake; S Ashley Roberts Journal: Eur J Radiol Date: 2014-04-13 Impact factor: 3.528
Authors: C Möbius; H J Stein; C Spiess; I Becker; M Feith; J Theisen; P Gais; U Jütting; J R Siewert Journal: Eur J Surg Oncol Date: 2005-09 Impact factor: 4.424
Authors: Eva Henriksson; Elisabeth Kjellen; Peter Wahlberg; Tomas Ohlsson; Johan Wennerberg; Eva Brun Journal: Anticancer Res Date: 2007 Jul-Aug Impact factor: 2.480
Authors: L H McCormick Matthews; F Noble; J Tod; E Jaynes; S Harris; J N Primrose; C Ottensmeier; G J Thomas; T J Underwood Journal: Br J Cancer Date: 2015-06-25 Impact factor: 7.640
Authors: Emad A Rakha; Sarah E Pinder; John M S Bartlett; Merdol Ibrahim; Jane Starczynski; Pauline J Carder; Elena Provenzano; Andrew Hanby; Sally Hales; Andrew H S Lee; Ian O Ellis Journal: J Clin Pathol Date: 2014-12-08 Impact factor: 3.411